Vera Therapeutics Names Jane Wright-Mitchell as CLO Ahead of Atacicept Launch
Jane Wright-Mitchell, Pharm.D., J.D., with over 25 years advising life sciences companies, has been appointed Chief Legal Officer at Vera Therapeutics, effective immediately. Her expertise in regulatory approvals, commercialization and intellectual property management will support the upcoming potential launch of Vera’s first-in-class dual BAFF/APRIL inhibitor atacicept for IgA nephropathy.
1. Appointment of Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer effective immediately. Wright-Mitchell brings over 25 years of legal and compliance experience in the life sciences industry, having served as General Counsel and Chief Compliance Officer at Vaxcyte and as a fractional general counsel supporting public and private biotech firms.
2. Strengthening Regulatory and Commercial Strategy
Wright-Mitchell’s track record in securing regulatory approvals, managing intellectual property and overseeing commercialization will be critical as Vera advances toward the potential launch of atacicept, its first-in-class dual BAFF/APRIL inhibitor targeting IgA nephropathy, to ensure a robust foundation for market entry and sustainable growth.